Were the first country to get these generics, although we likely wont see them before the summer (you can thank Health Canadas approval backlog for that)
In summary, this result showed that GSTM3 is remarkably correlated with the proliferation capacity of PDAC and exerted an important role in PDAC progression
Oct1 Polyspecificity-friend or foe
Secondary outcomes included frequency of dose reductions and discontinuations, achievement of clinical goals, and presence of an embedded clinical pharmacist at patients primary care office
However, as noted by Mahiques-Santos, while melanotan II has been investigated as a potential ED treatment, it has been largely superseded by a nasally administered molecule (PT-141, link), an active metabolite of the molecule [1]